Patents by Inventor Michael Duelund Soerensen

Michael Duelund Soerensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1 COMPOSITIONS AND USES THEREOF
    Publication number: 20240016896
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Application
    Filed: July 26, 2023
    Publication date: January 18, 2024
    Applicant: Novo Nordisk A/S
    Inventors: Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist
  • GLP-1 compositions and uses thereof
    Patent number: 11752198
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: September 12, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist
  • Liquid Pharmaceutical Formulations of PTH Conjugates
    Publication number: 20220088149
    Abstract: A liquid pharmaceutical formulation, wherein the pharmaceutical formulation comprises a PTH conjugate, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and wherein the PTH conjugate comprises a PTH moiety that is covalently and reversibly conjugated to a water-soluble carrier moiety.
    Type: Application
    Filed: February 10, 2020
    Publication date: March 24, 2022
    Inventors: Anja R.H. SKANDS, Felix CLEEMANN, Michael Duelund SØRENSEN, Julia BARON, Eric HOFFMANN, Kennett SPROGØE
  • GLP-1 COMPOSITIONS AND USES THEREOF
    Publication number: 20210085755
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 25, 2021
    Inventors: Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist
  • GLP-1 compositions and uses thereof
    Patent number: 10888605
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: January 12, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist
  • GLP-1 COMPOSITIONS AND USES THEREOF
    Publication number: 20200164042
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Application
    Filed: January 28, 2020
    Publication date: May 28, 2020
    Inventors: Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist